APO Research
Talk to an analyst

APO RESEARCH · REPORT

Apatinib

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Apatinib Market Outlook and Growth Opportunities 2026

23 December 2025192 pages

Choose your research edition.

Industry ResearchApatinib Industry Research Report 2026107 pages · $2,950 USDIndustry Growth & TrendsGlobal Apatinib Industry Growth and Trends Forecast to 203273 pages · $3,450 USDMarket StructureGlobal Apatinib Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032177 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Apatinib Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Apatinib Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Apatinib market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Apatinib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Apatinib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Apatinib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Apatinib market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Apatinib market include Jiangsu Hengrui Medicine, LSK BioPartners, Bukwang Pharmaceutical Company and Advenchen Laboratories, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Apatinib market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Apatinib and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Apatinib sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Apatinib market size, projected growth trends, production technologies, key applications, and end-use industries.

Apatinib Segment by Company

Jiangsu Hengrui Medicine

LSK BioPartners

Bukwang Pharmaceutical Company

Advenchen Laboratories

Apatinib Segment by Type

0.25g/Pcs

0.425g/Pcs

0.375g/Pcs

Apatinib Segment by Application

Advanced Hepatocellular Carcinoma

Metastatic Breast Cancer

Metastatic Gastric Carcinoma

Others

Apatinib Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Apatinib status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Apatinib market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Apatinib significant trends, drivers, influence factors in global and regions.

6. To analyze Apatinib competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Apatinib market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Apatinib and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Apatinib.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Apatinib market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Apatinib industry.

Chapter 3: Detailed analysis of Apatinib manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Apatinib in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Apatinib in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Apatinib Industry Trends Table 2. Apatinib Industry Drivers Table 3. Apatinib Industry Opportunities and Challenges Table 4. Apatinib Industry Restraints Table 5. Global Apatinib Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Apatinib Revenue Share by Company (2021-2026) Table 7. Global Apatinib Sales Volume by Company (k pcs) & (2021-2026) Table 8. Global Apatinib Sales Volume Share by Company (2021-2026) Table 9. Global Apatinib Average Price (US$/pcs) of Company (2021-2026) Table 10. Global Apatinib Company Ranking, (2024-2026) & (USD Million) Table 11. Global Apatinib Key Company Manufacturing Base & Headquarters Table 12. Global Apatinib Company, Product Type & Application Table 13. Global Apatinib Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Apatinib by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 0.25g/Pcs Table 18. Significant Companies of 0.425g/Pcs Table 19. Significant Companies of 0.375g/Pcs Table 20. Global Apatinib Sales Volume by Type 2021 VS 2025 VS 2032 (k pcs) Table 21. Global Apatinib Sales Volume by Type (2021-2026) & (k pcs) Table 22. Global Apatinib Sales Volume by Type (2027-2032) & (k pcs) Table 23. Global Apatinib Sales Volume Share by Type (2021-2026) Table 24. Global Apatinib Sales Volume Share by Type (2027-2032) Table 25. Global Apatinib Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Apatinib Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Apatinib Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Apatinib Sales Value Share by Type (2021-2026) Table 29. Global Apatinib Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Advanced Hepatocellular Carcinoma Table 31. Significant Companies of Metastatic Breast Cancer Table 32. Significant Companies of Metastatic Gastric Carcinoma Table 33. Significant Companies of Others Table 34. Global Apatinib Sales Volume by Application 2021 VS 2025 VS 2032 (k pcs) Table 35. Global Apatinib Sales Volume by Application (2021-2026) & (k pcs) Table 36. Global Apatinib Sales Volume by Application (2027-2032) & (k pcs) Table 37. Global Apatinib Sales Volume Share by Application (2021-2026) Table 38. Global Apatinib Sales Volume Share by Application (2027-2032) Table 39. Global Apatinib Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Apatinib Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Apatinib Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Apatinib Sales Value Share by Application (2021-2026) Table 43. Global Apatinib Sales Value Share by Application (2027-2032) Table 44. Global Apatinib Sales by Region: 2021 VS 2025 VS 2032 (k pcs) Table 45. Global Apatinib Sales by Region (2021-2026) & (k pcs) Table 46. Global Apatinib Sales Market Share by Region (2021-2026) Table 47. Global Apatinib Sales by Region (2027-2032) & (k pcs) Table 48. Global Apatinib Sales Market Share by Region (2027-2032) Table 49. Global Apatinib Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Apatinib Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Apatinib Sales Value Share by Region (2021-2026) Table 52. Global Apatinib Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Apatinib Sales Value Share by Region (2027-2032) Table 54. Global Apatinib Market Average Price (US$/pcs) by Region (2021-2026) Table 55. Global Apatinib Market Average Price (US$/pcs) by Region (2027-2032) Table 56. Global Apatinib Sales by Country: 2021 VS 2025 VS 2032 (k pcs) Table 57. Global Apatinib Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Apatinib Sales by Country (2021-2026) & (k pcs) Table 59. Global Apatinib Sales Market Share by Country (2021-2026) Table 60. Global Apatinib Sales by Country (2027-2032) & (k pcs) Table 61. Global Apatinib Sales Market Share by Country (2027-2032) Table 62. Global Apatinib Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Apatinib Sales Value Market Share by Country (2021-2026) Table 64. Global Apatinib Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Apatinib Sales Value Market Share by Country (2027-2032) Table 66. Jiangsu Hengrui Medicine Company Information Table 67. Jiangsu Hengrui Medicine Business Overview Table 68. Jiangsu Hengrui Medicine Apatinib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 69. Jiangsu Hengrui Medicine Apatinib Product Portfolio Table 70. Jiangsu Hengrui Medicine Recent Development Table 71. LSK BioPartners Company Information Table 72. LSK BioPartners Business Overview Table 73. LSK BioPartners Apatinib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 74. LSK BioPartners Apatinib Product Portfolio Table 75. LSK BioPartners Recent Development Table 76. Bukwang Pharmaceutical Company Company Information Table 77. Bukwang Pharmaceutical Company Business Overview Table 78. Bukwang Pharmaceutical Company Apatinib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 79. Bukwang Pharmaceutical Company Apatinib Product Portfolio Table 80. Bukwang Pharmaceutical Company Recent Development Table 81. Advenchen Laboratories Company Information Table 82. Advenchen Laboratories Business Overview Table 83. Advenchen Laboratories Apatinib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 84. Advenchen Laboratories Apatinib Product Portfolio Table 85. Advenchen Laboratories Recent Development Table 86. Key Raw Materials Table 87. Raw Materials Key Suppliers Table 88. Apatinib Distributors List Table 89. Apatinib Customers List Table 90. Research Programs/Design for This Report Table 91. Authors List of This Report Table 92. Secondary Sources Table 93. Primary Sources List of Figures Figure 1. Apatinib Product Image Figure 2. Global Apatinib Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Apatinib Sales Value (2021-2032) & (US$ Million) Figure 4. Global Apatinib Sales (2021-2032) & (k pcs) Figure 5. Global Apatinib Sales Average Price (US$/pcs) & (2021-2032) Figure 6. Global Apatinib Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 0.25g/Pcs Image Figure 10. 0.425g/Pcs Image Figure 11. 0.375g/Pcs Image Figure 12. Global Apatinib Sales Volume by Type (2021 VS 2025 VS 2032) & (k pcs) Figure 13. Global Apatinib Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Apatinib Sales Volume Share by Type (2021-2032) Figure 15. Global Apatinib Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Apatinib Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Apatinib Sales Value Share by Type (2021-2032) Figure 18. Advanced Hepatocellular Carcinoma Image Figure 19. Metastatic Breast Cancer Image Figure 20. Metastatic Gastric Carcinoma Image Figure 21. Others Image Figure 22. Global Apatinib Sales Volume by Application (2021 VS 2025 VS 2032) & (k pcs) Figure 23. Global Apatinib Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Apatinib Sales Volume Share by Application (2021-2032) Figure 25. Global Apatinib Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Apatinib Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Apatinib Sales Value Share by Application (2021-2032) Figure 28. Global Apatinib Sales by Region: 2021 VS 2025 VS 2032 (k pcs) Figure 29. Global Apatinib Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Apatinib Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Apatinib Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Apatinib Sales Value (2021-2032) & (US$ Million) Figure 33. North America Apatinib Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Apatinib Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Apatinib Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Apatinib Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Apatinib Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Apatinib Sales Value (2021-2032) & (US$ Million) Figure 39. South America Apatinib Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Apatinib Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Apatinib Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Apatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Apatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Apatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Apatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Apatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Apatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Apatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Apatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Apatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Apatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Apatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Apatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Apatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Apatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Apatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Apatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Apatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Apatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Apatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Apatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Apatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Apatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Apatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Apatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Apatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Apatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Apatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Apatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Apatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Apatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Apatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Apatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Apatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Apatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Apatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Apatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Apatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Apatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Apatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Apatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Apatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Apatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Apatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Apatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Apatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Apatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Apatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Apatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Apatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Apatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Apatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Apatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Apatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Apatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Apatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Apatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Apatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Apatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Apatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Apatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Apatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Apatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Apatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Apatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Apatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Apatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Apatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Apatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Apatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Apatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Apatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Apatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Apatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Apatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Apatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Apatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Apatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Apatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Apatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Apatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Apatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Apatinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Apatinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Apatinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Apatinib Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Apatinib Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • 0.25g/Pcs
  • 0.425g/Pcs
  • 0.375g/Pcs
Applications
  • Advanced Hepatocellular Carcinoma
  • Metastatic Breast Cancer
  • Metastatic Gastric Carcinoma
  • Others
Companies covered
  • Jiangsu Hengrui Medicine
  • LSK BioPartners
  • Bukwang Pharmaceutical Company
  • Advenchen Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Apatinib Sales Value (2021-2032)
  4. 1.2.2 Global Apatinib Sales Volume (2021-2032)
  5. 1.2.3 Global Apatinib Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Apatinib Market Dynamics
  1. 2.1 Apatinib Industry Trends
  2. 2.2 Apatinib Industry Drivers
  3. 2.3 Apatinib Industry Opportunities and Challenges
  4. 2.4 Apatinib Industry Restraints
3 Apatinib Market by Company
  1. 3.1 Global Apatinib Company Revenue Ranking in 2025
  2. 3.2 Global Apatinib Revenue by Company (2021-2026)
  3. 3.3 Global Apatinib Sales Volume by Company (2021-2026)
  4. 3.4 Global Apatinib Average Price by Company (2021-2026)
  5. 3.5 Global Apatinib Company Ranking (2024-2026)
  6. 3.6 Global Apatinib Company Manufacturing Base and Headquarters
  7. 3.7 Global Apatinib Company Product Type and Application
  8. 3.8 Global Apatinib Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Apatinib Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Apatinib Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Apatinib Market by Type
  1. 4.1 Apatinib Type Introduction
  2. 4.1.1 0.25g/Pcs
  3. 4.1.2 0.425g/Pcs
  4. 4.1.3 0.375g/Pcs
  5. 4.2 Global Apatinib Sales Volume by Type
  6. 4.2.1 Global Apatinib Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Apatinib Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Apatinib Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Apatinib Sales Value by Type
  10. 4.3.1 Global Apatinib Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Apatinib Sales Value by Type (2021-2032)
  12. 4.3.3 Global Apatinib Sales Value Share by Type (2021-2032)
5 Apatinib Market by Application
  1. 5.1 Apatinib Application Introduction
  2. 5.1.1 Advanced Hepatocellular Carcinoma
  3. 5.1.2 Metastatic Breast Cancer
  4. 5.1.3 Metastatic Gastric Carcinoma
  5. 5.1.4 Others
  6. 5.2 Global Apatinib Sales Volume by Application
  7. 5.2.1 Global Apatinib Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Apatinib Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Apatinib Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Apatinib Sales Value by Application
  11. 5.3.1 Global Apatinib Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Apatinib Sales Value by Application (2021-2032)
  13. 5.3.3 Global Apatinib Sales Value Share by Application (2021-2032)
6 Apatinib Regional Sales and Value Analysis
  1. 6.1 Global Apatinib Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Apatinib Sales by Region (2021-2032)
  3. 6.2.1 Global Apatinib Sales by Region: 2021-2026
  4. 6.2.2 Global Apatinib Sales by Region (2027-2032)
  5. 6.3 Global Apatinib Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Apatinib Sales Value by Region (2021-2032)
  7. 6.4.1 Global Apatinib Sales Value by Region: 2021-2026
  8. 6.4.2 Global Apatinib Sales Value by Region (2027-2032)
  9. 6.5 Global Apatinib Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Apatinib Sales Value (2021-2032)
  12. 6.6.2 North America Apatinib Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Apatinib Sales Value (2021-2032)
  15. 6.7.2 Europe Apatinib Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Apatinib Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Apatinib Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Apatinib Sales Value (2021-2032)
  21. 6.9.2 South America Apatinib Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Apatinib Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Apatinib Sales Value Share by Country, 2025 VS 2032
7 Apatinib Country-level Sales and Value Analysis
  1. 7.1 Global Apatinib Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Apatinib Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Apatinib Sales by Country (2021-2032)
  4. 7.3.1 Global Apatinib Sales by Country (2021-2026)
  5. 7.3.2 Global Apatinib Sales by Country (2027-2032)
  6. 7.4 Global Apatinib Sales Value by Country (2021-2032)
  7. 7.4.1 Global Apatinib Sales Value by Country (2021-2026)
  8. 7.4.2 Global Apatinib Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Apatinib Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Apatinib Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Apatinib Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Apatinib Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Apatinib Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Apatinib Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Apatinib Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Apatinib Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Apatinib Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Apatinib Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Apatinib Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Apatinib Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Apatinib Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Apatinib Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Apatinib Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Apatinib Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Apatinib Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Apatinib Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Apatinib Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Apatinib Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Apatinib Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Apatinib Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Apatinib Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Apatinib Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Apatinib Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Apatinib Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Apatinib Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Apatinib Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Apatinib Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Apatinib Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Apatinib Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Apatinib Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Apatinib Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Apatinib Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Apatinib Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Apatinib Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Apatinib Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Apatinib Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Apatinib Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Apatinib Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Apatinib Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Apatinib Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Apatinib Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Apatinib Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Apatinib Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Apatinib Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Apatinib Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Apatinib Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Apatinib Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Apatinib Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Apatinib Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Apatinib Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Apatinib Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Apatinib Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Apatinib Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Apatinib Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Apatinib Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Apatinib Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Apatinib Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Apatinib Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Apatinib Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Apatinib Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Apatinib Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Apatinib Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Apatinib Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Apatinib Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Apatinib Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Apatinib Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Apatinib Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Apatinib Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Apatinib Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Apatinib Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Apatinib Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Apatinib Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Apatinib Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Apatinib Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Apatinib Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Apatinib Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Apatinib Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Apatinib Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Apatinib Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Apatinib Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Apatinib Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Apatinib Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Jiangsu Hengrui Medicine
  2. 8.1.1 Jiangsu Hengrui Medicine Company Information
  3. 8.1.2 Jiangsu Hengrui Medicine Business Overview
  4. 8.1.3 Jiangsu Hengrui Medicine Apatinib Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Jiangsu Hengrui Medicine Apatinib Product Portfolio
  6. 8.1.5 Jiangsu Hengrui Medicine Recent Developments
  7. 8.2 LSK BioPartners
  8. 8.2.1 LSK BioPartners Company Information
  9. 8.2.2 LSK BioPartners Business Overview
  10. 8.2.3 LSK BioPartners Apatinib Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 LSK BioPartners Apatinib Product Portfolio
  12. 8.2.5 LSK BioPartners Recent Developments
  13. 8.3 Bukwang Pharmaceutical Company
  14. 8.3.1 Bukwang Pharmaceutical Company Company Information
  15. 8.3.2 Bukwang Pharmaceutical Company Business Overview
  16. 8.3.3 Bukwang Pharmaceutical Company Apatinib Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Bukwang Pharmaceutical Company Apatinib Product Portfolio
  18. 8.3.5 Bukwang Pharmaceutical Company Recent Developments
  19. 8.4 Advenchen Laboratories
  20. 8.4.1 Advenchen Laboratories Company Information
  21. 8.4.2 Advenchen Laboratories Business Overview
  22. 8.4.3 Advenchen Laboratories Apatinib Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Advenchen Laboratories Apatinib Product Portfolio
  24. 8.4.5 Advenchen Laboratories Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Apatinib Value Chain Analysis
  2. 9.1.1 Apatinib Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Apatinib Sales Mode & Process
  6. 9.2 Apatinib Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Apatinib Distributors
  9. 9.2.3 Apatinib Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst